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Microphthalmia-Associated Transcription Factor: 
A Central Regulator of Pigment Epithelium-Derived Factor 
Controlling Human Melanoma Progression 
 
To the Editor-in-Chief: 
We read with great interest the article by Dadras et al in The American Journal of 
Pathology describing microphthalmiaassociated transcription factor (MITF) as a 
regulator of pigment epithelium-derived factor (PEDF) in human melanoma. Although 
we are pleased to see that the authors have confirmed our recent results, we feel that 
the authors overlooked a careful review of the concurrent literature on the biological 
role of PEDF during melanoma progression and the identification of MITF as a 
transcriptional regulator of PEDF. First, Dadras et al state in their abstract that “PEDF 
expression and/or regulation during melanoma development have not been 
investigated previously.” This statement is inaccurate, as our group and another have 
previously addressed this point. Specifically, by performing a highthroughput analysis 
of the data from molecular profiling studies of human melanoma cell lines, we 
demonstrated that PEDF is highly expressed in melanocytes and low aggressive 
melanoma cells but is lost in highly aggressive melanomas. Furthermore, we studied 
paired cell lines isolated from human metastatic lesions displaying extreme phenotypes 
and demonstrated that PEDF expression is restricted to the less aggressive 
counterparts. In mouse models of human melanoma metastases, we established that 
PEDF levels critically impact melanoma progression by gain and loss of function 
experiments (PEDF overexpression or silencing, respectively). The mention of a 
subsequent study identifying the mechanisms by which PEDF exerts its antimetastatic 
actions is also missing from the article by Dadras et al. Importantly, this study showed 
that PEDF is able to efficiently block two modes of melanoma invasion by suppressing 
ameboid morphology and mesenchymal proteolysis. Second, Dadras et al show that 
PEDF is a direct transcriptional target of MITF in human melanocytes and melanoma 
cells but overstate the novelty of their discoveries. We have recently demonstrated that 
PEDF expression positively correlates with MITF during human melanoma progression. 
Of note, we showed that oncogene-induced senescence promotes down-regulation of 
PEDF and MITF in primary melanocytes, providing a likely explanation to the lack of 
PEDF and MITF expression in nevi described in our article and confirmed by Dadras et 
al. Furthermore, we identified three MITF regulatory sites in the first intron of 
SERPINF1 based on published ChIP-seq data that were further validated by an 
independent ChIP-seq experiment and reporter assays that revealed that at least two 
of the identified MITF-binding sites have functional activity. Importantly, our study also 
provided a functional connection between MITF and PEDF, which is critical for 
melanoma dissemination. Using an established zebrafish model of metastasis, we 
demonstrated that in vivo dissemination of human melanoma cells induced by MITF 
silencing is halted by PEDF sustained expression, providing solid evidence for the role 
of the MITFePEDF axis in the control of melanoma biology. In summary, we believe 
that the article published by Dadras et al lacks a complete description of the previous 
findings describing the biological role of PEDF and its regulation by MITF during human 
melanoma progression. We consider it important to highlight these references to the 
readers of the Journal. 
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